Unknown

Dataset Information

0

Transcriptional effects of 177Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice.


ABSTRACT: BACKGROUND:177Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors with promising results, although complete tumor remission is rarely seen. Previous studies on nude mice bearing the human small intestine neuroendocrine tumor, GOT1, have shown that a priming injection of 177Lu-octreotate 24?h before the main injection of 177Lu-octreotate resulted in higher 177Lu concentration in tumor, resulting in increased absorbed dose, volume reduction, and time to regrowth. To our knowledge, the cellular effects of a priming treatment schedule have not yet been studied. The aim of this study was to identify transcriptional changes contributing to the enhanced therapeutic response of GOT1 tumors in nude mice to 177Lu-octreotate therapy with priming, compared with non-curative monotherapy. RESULTS:RNA microarray analysis was performed on tumor samples from GOT1-bearing BALB/c nude mice treated with a 5?MBq priming injection of 177Lu-octreotate followed by a second injection of 10?MBq of 177Lu-octreotate after 24?h and killed after 1, 3, 7, and 41 days after the last injection. Administered activity amounts were chosen to be non-curative, in order to facilitate the study of tumor regression and regrowth. Differentially regulated transcripts (RNA samples from treated vs. untreated animals) were identified (change ??1.5-fold; adjusted p value

SUBMITTER: Spetz J 

PROVIDER: S-EPMC6426909 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Transcriptional effects of <sup>177</sup>Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice.

Spetz Johan J   Langen Britta B   Rudqvist Nils-Petter NP   Parris Toshima Z TZ   Shubbar Emman E   Dalmo Johanna J   Wängberg Bo B   Nilsson Ola O   Helou Khalil K   Forssell-Aronsson Eva E  

EJNMMI research 20190320 1


<h4>Background</h4><sup>177</sup>Lu-octreotate is used for therapy of somatostatin receptor expressing neuroendocrine tumors with promising results, although complete tumor remission is rarely seen. Previous studies on nude mice bearing the human small intestine neuroendocrine tumor, GOT1, have shown that a priming injection of <sup>177</sup>Lu-octreotate 24 h before the main injection of <sup>177</sup>Lu-octreotate resulted in higher <sup>177</sup>Lu concentration in tumor, resulting in increas  ...[more]

Similar Datasets

| S-EPMC5549301 | biostudies-other
| S-EPMC5241264 | biostudies-literature
2017-12-31 | GSE80021 | GEO
2017-03-08 | GSE80022 | GEO
| S-EPMC6391910 | biostudies-literature
2014-03-05 | GSE44762 | GEO
2014-03-05 | E-GEOD-44762 | biostudies-arrayexpress
| S-EPMC4546116 | biostudies-literature
| S-EPMC5973847 | biostudies-other
| S-EPMC2764054 | biostudies-other